Introduction
Breast cancer is the most frequent form of cancer diagnosed in women, second only to nonmelanoma forming skin cancers (1) . Increases in awareness coupled with the rate and efficacy of mammogram screenings has increasingly allowed for the detection of breast cancers. One third of newly diagnosed cases have detected the presence of breast malignancies in the initial stages with tumours less than 1 cm in size (2) . Although these trends do indicate a positive direction with regard to disease detection, there still remains a significant fraction of the population in which diagnosis is not made until later stages, with 5-20% of newly diagnosed cases being classified as locally advanced breast cancer (LABC) (3, 4) , and with even greater numbers outside of North America. Locally advanced breast cancer typically comprises all stage III and a subset of stage IIB (T3N0) tumours and are diagnosed as tumours which are frequently greater than 5 cm, involving the chest wall and/or classified as inflammatory breast cancer. Due to the progression of the disease and high risk for metastatic spread, LABC patients typically have poor long-term survival rates (five-year survival rate of 55%, approximately) in comparison to the early stages patients (4) .
Current methods of assessing patient responses to cancer therapy are based upon ascertaining physical measurements of the tumour during treatment. These methods include clinical examination, X-ray mammography, conventional ultrasound imaging and magnetic resonance imaging (MRI). Physical examination by palpation is commonly employed by clinicians; however this method of tumour assessment is subjective (5) . During the course of the last several decades, X-ray mammography has made considerable improvements in the detection of breast cancers but has not shown significant promise in tracking tumour response during treatment.
MRI is commonly employed for assessing the end result of treatment in LABC patients as it
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However it remains a costly imaging modality to employ. Another limitation stems from the fact that these methods attempt to ascertain patient response to treatment by determining the physical size of the tumour. Tumour size reduction, however, frequently requires several weeks to months of treatment administration and in some cases mass diminishment is not present despite a cytotoxic treatment response (6) .
Changes in tumour size with treatment are the late cumulative result of early micro-structural changes in tumour cell morphology often due to cell death, starting to take place within hours to days after treatment administration. This then provides the possibility of assessing the early effects of a treatment on a tumour to monitor therapy efficacy, in advance of changes to the overall tumour volume. Thus the advent of a non-invasive functional method to monitor patient responses to therapy would be advantageous in order to guide the customization of chemotherapy or other cancer therapies on an individual patient basis. Alternatively, such imaging methods could also facilitate a switch to an early salvage therapy for patients whose responses to the current therapy are determined to be limited.
Research into the potential of ultrasound to monitor non-invasively the effects of cancer therapy administration was initially conducted using high-frequency (20-50 MHz) ultrasound and demonstrated its capacity to detect changes in tissue microstructure associated with a variety of cancer therapies in in vitro, in situ, and in vivo models (7) (8) (9) (10) (11) (12) (13) (14) . Initial in vitro observations indicated increases in tissue echogenicity in acute myeloid leukemia (AML) cells exposed to the chemotherapeutic agent cisplatin (7, 8 dependant experiments (9, 10) . To date, high-frequency ultrasound has been used to detect apoptotic cell death resulting from photodynamic, X-ray radiation and ultrasonically activated anti-vascular micro-bubble therapies in a variety of in vivo mouse models (12) (13) (14) . These studies demonstrated up to 16-fold maximal increases in observed backscatter signal intensity accompanied by increases in spectral parameters such as spectral slope, 0-MHz intercept, and mid-band fit (MBF) quantitative parameters which can be related to effective scatterer size, acoustic concentration, and both, respectively (15, 16) . Similar techniques have been applied previously in a variety of other ultrasound tissue characterization applications, such as the differentiation of mammary carcinomas and sarcomas from benign fibroadenomas, and the diagnoses of cardiac and liver abnormalities, and prostate cancer (17) (18) (19) (20) .
High-frequency 20-50 MHz ultrasound benefits from an increased imaging resolution μm) when compared to clinically employed conventional-frequencies of 1 to 20 MHz (80 μm -1.5 mm). However, it suffers from a limited tissue penetration depth, restricting its use to superficial tissue sites near the skin surface. On the other hand, while the application of conventional-frequency ultrasound carries a decreased imaging resolution, it benefits from a substantive tissue penetration capacity. Such an advantage potentially allows to non-invasively monitoring the effects of therapy on deeper malignant tissues such as breast, kidney and liver cancerous tumours. This has motivated a number of recent studies into the capacity of conventional-frequency ultrasound in the detection of cancer treatment effects, effectively laying the groundwork for this clinical evaluation (21) (22) (23) .
In this study, the potential of conventional-frequency ultrasound has been investigated for the first time, to non-invasively monitor the effects of clinical cancer treatment in patients. Locally advanced breast cancer patients receiving neo-adjuvant chemotherapy were monitored during 
Materials and Methods

Study Protocol and Data Collection
This study was conducted with research ethics approval and was open to all women with locally advanced breast cancer aged 18 to 85 meeting study criteria. Ultrasound data was acquired at 5 times during the patients' course of treatment. The first scan was acquired immediately prior to the start of chemotherapy which was used as a baseline of comparison for subsequent scans. The following three scans were acquired during the first, fourth and eighth week of treatment, with a fifth scan acquired within one week prior to the modified radical mastectomy surgery, typically occurring four to six weeks after the course of treatment was completed.
All the ultrasound data in this study were collected by the same sonographer following standardized protocols for data acquisition. Ultrasound data was acquired with patients lying supine with their arms above their heads. Conventional B-Mode and radiofrequency ultrasound data were acquired using a Sonix RP, (Ultrasonix Vancouver, Canada) system utilizing a L14-5/60 transducer transmitting pulses with a 50% duty factor over 50 ns, exciting transducer elements with a frequency of 10 MHz, and resulting in a frequency bandwidth with a centre frequency of ~7 MHz. The transducer focus was set at varying depths depending on individual patient circumstances and digital radiofrequency data acquired with a sampling frequency of 40
MHz. Scan focal depths remained consistent for individual patients throughout the study. Breast there was a decrease in tumour size of 30% or more, and included patients which were deemed to have a complete pathological response to treatment (no residual invasive carcinoma) (25) .
Conversely, patients were deemed to be non-responders if there was less than a 30% decrease in tumour size and included patients with progressive disease in which the tumour volume increased despite treatment (25) . In cases where the tumour cellularity was very low (overall volume of viable tumour cells), the patient was considered as a responder as well, even if the diminishment in the physical tumour size was less than 30%. In contrast, in cases where tumour 
Data Analysis
Ultrasound radiofrequency data analysis was performed using linear regression analysis of the normalized power spectrum (7) (8) (9) (10) (11) (12) (13) (14) (15) (17) (18) (19) (20) . Ultrasound data was analyzed across all acquired planes through the scan volume which included identifiable tumour regions. Analysis parameters were reported from data within a region of interest (ROI) located at the tumour central area which was consistently positioned at the transducer focal depth, typically accounting for approximately two third of the tumour area in cross-sectional plane.
The power spectrum was calculated using a Fourier transform of the raw radiofrequency data for each scan line through the whole field of view of the ultrasound data (described further below). In order to remove the effects of system transfer functions, transducer beam-forming, and diffraction artefacts, in addition to acting as a mechanism of depth related attenuation correction, data were normalized using a sliding window analysis with the power spectrum obtained from an agar embedded glass bead phantom model, modified from (26) , with properties similar to those of breast tissue. Phantom data was acquired for each setting used during patient data acquisition, including variations in image gain and focal depth. Linear regression analysis was performed within the -6 dB window centered at the transducer central frequency, which was determined from a calibration pulse, to generate a best-fit line. Parameters subsequently reported included the mid-band fit (MBF), the spectral slope, and the corresponding 0-MHz intercept (16, (27) (28) (29) . Parameters were determined for each of the scan planes collected per patient visit and subsequently averaged across the tumour volume.
Specifically, spectral parameters for each scan plane were determined through averaging on the parametric images generated using a sliding window analysis on a pixel by pixel basis. Each sliding window was normalized separately to a reference curve obtained from the same region of 
Results
Patient Characteristics and Clinical/Pathological Treatment Response
Characteristics of the participating patients, as well as their tumour properties, and the treatments administrated are summarized in Table 1A categorized as responders. In the case of patients 2, and 17 the reduction in physical tumour or mass size was less than 30%, however residual tumour cellularity was very low and these patients were clinically/pathologically classified as responders. Patients 6, 9, 11, 12, and 22 were non-responses. They demonstrated progressive disease, or their tumour size only slightly changed during treatment. In the case of patient 3, whereas the reduction in tumour size was slightly more than 30%, the tumour cellularity in the residual mass remained very high. As such, this patient was also classified as a non-responder clinically and pathologically.
on
Quantitative Ultrasound Evaluation of Treatment Response
Representative ultrasound B-mode images, and the spectral parametric images, acquired from a responding patient with locally advanced breast cancer tumour prior to the start of chemotherapy onset, and after four weeks of treatment, are presented in Figure 1A . An overall increase in the ultrasound spectral backscatter power was detectable within the tumour region, as also presented in the MBF and 0-MHz parametric images. Normalized power spectra and generalized gamma fits on the histograms of the MBF intensity for the representative tumour region is also presented in Figure 1B . Figure 1C demonstrates representative 0-MHz parametric images corresponding to non-responder and responding patients, acquired from the same nominal breast tumour regions during treatment. Whereas considerable changes were visualized over the course of treatment in the parametric images that correspond to the responding patients, no such striking change was observed in the case of the non-responding patients. Representative light microscopy images of whole-mount histopathology obtained following modified radical mastectomy surgery are given in Figure 2 , for a responding and a non-responding patient.
Contrary to the case of the responding patient, the whole-mount histopathology sample corresponding to the non-responding patient indicates a large compact residual mass in the mastectomy specimen, in both haematoxylin and eosin (H&E) stained slide and the slide stained to highlight positive estrogen receptor (ER+) areas. There were differences also observed in the trend of their corresponding MBF parameters, measured over the course of treatment for these patients. Whereas the responding patient exhibited an average increase of up to ~19 dBr (logarithmic unit for normalized power relative to a reference phantom) in MBF at weeks 4 to 8 of chemotherapy, the non-responding patient did not demonstrate such a considerable change (only up to ~5 dBr) in this quantitative parameter during the course of treatment. Average data obtained from treatment responding and non-responding patients over the course of treatment is presented in Figure 3 . The results indicate a substantial increase in the ultrasound spectral backscatter power acquired from the patients that responded to the treatment.
Mean increases in MBF in responding patients were measured as 3.5 ± 1.1 dBr, 9.1 ± 1.2 dBr, 8.6 ± 1.4 dBr, 1.2 ± 2.3 dBr in the first, fourth, eighth week of treatment, and pre-operatively, respectively. Results from patients who did not respond to chemotherapy were measured as 0.3 ± 1.9 dBr, 1.9 ± 1.1 dBr, 3.3 ± 1.5 dBr, -1. 
ultimate treatment response in patients undergoing cancer-targeting therapies. Such an early prediction could be used to facilitate the critical decision of switching to a more effective therapy for the treatment refractory patients, early during the course of treatment.
Changes in the quantitative ultrasound spectral parameters from the baseline are expected to mainly show the development of response (apoptotic cell death) for each patient (as further discussed below). At the eighth week of treatment, the non-responding patients may exhibit a late slight response to the treatment. In addition, a number of partial responders may have their tumour cells repopulated in partial regions demonstrating small response levels. As such having a relatively less separability between responding and non-responding patient populations can be expected. Results obtained in this study (Figure 3 ) demonstrated a lesser separability between these two patient populations prior to surgery (pre-op). This may be happening due to the fact that at this time, the neo-adjuvant chemotherapy has been stopped for several weeks, and thus minimal cell death is expected. Also the complete pathological responders, who have no residual tumour left in ultrasound scans, are not expected to show response and are excluded from the analysis at that time.
Previous in vitro and in vivo investigations of ultrasound-based cell death detection support the results presented in this study. The previous studies include those investigations where apoptosis was induced in cells and normal-tissues using a variety of modalities, and were analyzed using ultrasound data (7) (8) (9) (10) (11) (12) (13) (14) . It was demonstrated, that nuclear condensation by the induction of apoptotic death can result in increases in ultrasonic backscatter signal intensity, which is consistent with observations in this study. One might anticipate that measurable changes in backscatter characteristics from micron-sized particles are not expected at low-frequencies, essentially because of the weak scattering strength of small-size scatterers. However, bulk In this study changes in the MBF and the 0-MHz intercept followed general trends experimentally observed for higher ultrasound frequencies. Effects of larger scattering structures can affect the spectral slope and its invariance suggests than both small and large scattering structures play a role at these frequencies. We have previously demonstrated slope changes but only at high ultrasound frequencies (>20 MHz) when small scattering structures change their size (13) . Attenuation was accounted for in this study by a sliding window normalization process against a tissue-mimicking phantom under similar scan settings for every scan. In addition, the 0-MHz intercept, sensitive to the concentration of acoustic scatterers was determined parametrically for scans as it is believed to be free of attenuation effects (16) . Applications of other non-invasive imaging modalities for cancer treatment response monitoring have been investigated in previous studies, including those based on positron emission tomography (PET), magnetic resonance imaging, or diffuse optical imaging and spectroscopy (DOI/DOS) (6, (33) (34) (35) . Unlike PET and MRI based methods, the ultrasound method here relies on inherent contrast changes arising from changes in acoustical properties as cancer cells die, hence does not need the injection of any external contrast agents. Diffuse optical spectroscopy has recently been used to demonstrate the capability of distinguishing between treatment responsive and non-responding patients at the fourth week of chemotherapy (34) .
However, its lower resolution may lead to uncertainties for determining the tumour boundaries, specially in the case of smaller tumours. Ultrasound has the advantages of low cost, rapid imaging speed, high resolution, and portability and can access tumour location not easily visualized with that modality. 
